Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:SURE NASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSUREAdvisorShares Insiders Advantage ETF$140.98-2.0%$135.51$113.00▼$143.99$53.57M0.92264 shs427 shsTERNTerns Pharmaceuticals$52.95$51.03$2.65▼$53.19$6.12B-0.374.84 million shs6.35 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSUREAdvisorShares Insiders Advantage ETF0.00%-0.10%+2.68%+7.91%+23.42%TERNTerns Pharmaceuticals0.00%0.00%0.00%+23.66%+1,408.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSUREAdvisorShares Insiders Advantage ETF$140.98-2.0%$135.51$113.00▼$143.99$53.57M0.92264 shs427 shsTERNTerns Pharmaceuticals$52.95$51.03$2.65▼$53.19$6.12B-0.374.84 million shs6.35 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSUREAdvisorShares Insiders Advantage ETF0.00%-0.10%+2.68%+7.91%+23.42%TERNTerns Pharmaceuticals0.00%0.00%0.00%+23.66%+1,408.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSUREAdvisorShares Insiders Advantage ETF 2.69Moderate Buy$140.98N/ATERNTerns Pharmaceuticals 2.27Hold$55.144.13% UpsideCurrent Analyst Ratings BreakdownLatest SURE, HOYE, BPCR, and TERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/27/2026TERNTerns Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$58.004/26/2026TERNTerns Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/14/2026TERNTerns Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$44.00 ➝ $44.504/8/2026TERNTerns Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/7/2026TERNTerns Pharmaceuticals William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/31/2026TERNTerns Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$56.00 ➝ $53.003/30/2026TERNTerns Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$56.00 ➝ $53.003/27/2026TERNTerns Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026TERNTerns Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$53.003/27/2026TERNTerns Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSUREAdvisorShares Insiders Advantage ETFN/AN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$9.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSUREAdvisorShares Insiders Advantage ETFN/AN/A14.46N/AN/AN/AN/AN/AN/ATERNTerns Pharmaceuticals-$96.21M-$1.03N/AN/AN/AN/A-20.02%-19.37%N/ALatest SURE, HOYE, BPCR, and TERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/30/2026Q4 2025TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthSUREAdvisorShares Insiders Advantage ETF$1.290.92%N/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSUREAdvisorShares Insiders Advantage ETFN/AN/AN/ATERNTerns PharmaceuticalsN/A62.4162.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSUREAdvisorShares Insiders Advantage ETFN/ATERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipSUREAdvisorShares Insiders Advantage ETFN/ATERNTerns Pharmaceuticals1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableSUREAdvisorShares Insiders Advantage ETFN/A380,000N/ANot OptionableTERNTerns Pharmaceuticals40115.52 million113.79 millionNot OptionableSURE, HOYE, BPCR, and TERN HeadlinesRecent News About These CompaniesHow The Merck (MRK) Investment Story Is Shifting With Terns Deal And Oncology UpdatesMay 18, 2026 | finance.yahoo.comTerns Pharmaceuticals, Inc. $TERN Shares Purchased by Vanguard Group Inc.May 10, 2026 | marketbeat.comTerns Pharmaceuticals (NASDAQ:TERN) Upgraded to Sell at Wall Street ZenMay 9, 2026 | marketbeat.comStrs Ohio Takes $881,000 Position in Terns Pharmaceuticals, Inc. $TERNMay 8, 2026 | marketbeat.comMerck completes acquisition of Terns PharmaceuticalsMay 6, 2026 | pharmabiz.comPMSD (Merck) to acquire Terns Pharmaceuticals in USD 6.7 billion dealMay 6, 2026 | pharmiweb.comPMerck adds to cancer drug portfolio with new acquisitionMay 5, 2026 | wfmz.comWMerck Completes Acquisition of Terns Pharmaceuticals, Inc.May 5, 2026 | businesswire.comMerck's Keytruda Surge: A Boost Amid Acquisition CostsApril 30, 2026 | devdiscourse.comDMerck still sees ‘compelling’ outlook for Terns leukemia drugApril 30, 2026 | finance.yahoo.comOppenheimer downgrades Terns Pharmaceuticals (TERN)April 28, 2026 | msn.comTerns Pharmaceuticals gets FDA breakthrough status for leukemia drugApril 27, 2026 | investing.comTerns Pharmaceuticals Gets Breakthrough Designation for Leukemia TreatmentApril 27, 2026 | marketwatch.comBuy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?April 27, 2026 | zacks.comTerns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid LeukemiaApril 27, 2026 | globenewswire.comPharma giants see trial wins, EU approvals, and M&A progressApril 24, 2026 | msn.comMerck’s $6.7B Terns deal clears antitrust reviewApril 24, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN)April 21, 2026 | theglobeandmail.comTerns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERNApril 10, 2026 | businesswire.comWhy Terns Pharmaceuticals Stock Rocked the Market in MarchApril 8, 2026 | fool.comTerns rebuffed a higher bid before selling to MerckApril 7, 2026 | biopharmadive.comBNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs Small-Cap Outperformance Continues, These 2 ETFs Provide ExposureBy Jessica Mitacek | May 21, 2026Japan's Stealth Bull Market: How U.S. Investors Can Get ExposureBy Chris Markoch | May 17, 2026The Smarter Way to Invest in AI Without Taking Extreme RiskBy Chris Markoch | May 31, 2026The Power Grid Is Dying—Is It Time to Buy Its Replacement?By Jeffrey Neal Johnson | May 15, 2026The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearBy Chris Markoch | May 25, 2026SURE, HOYE, BPCR, and TERN Company DescriptionsAdvisorShares Insiders Advantage ETF NYSEARCA:SURE$140.98 -2.82 (-1.96%) As of 06/5/2026 04:10 PM EasternThe AdvisorShares Insider Advantage ETF (SURE) is an exchange-traded fund that mostly invests in total market equity. The fund is an actively managed portfolio of US stocks selected using a proprietary model that follows insider buying and stock buyback strategies. SURE was launched on Sep 1, 2022 and is managed by AdvisorShares.Terns Pharmaceuticals NASDAQ:TERNTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Petco Faces Tough Competition, But Momentum Is Building IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
